Stimulation of basal and L-DOPA-induced motor activity by glutamate antagonists in animal models of Parkinson's disease

MS Starr, BS Starr, S Kaur - Neuroscience & Biobehavioral Reviews, 1997 - Elsevier
MS Starr, BS Starr, S Kaur
Neuroscience & Biobehavioral Reviews, 1997Elsevier
In parkinsonism, glutamate pathways within the basal ganglia become overactive, leading to
the suggestion that glutamate antagonists might possess antiparkinsonian qualities. This
report examines the motor properties of antagonists of NMDA and AMPA-type glutamate
receptors, as well as some inhibitors of glutamate release, in animal models of idiopathic
Parkinson's disease. High affinity NMDA open-channel blockers (eg MK 801,
phencyclidine), are highly potent antagonists with inconsistent antiakinetic and strong …
In parkinsonism, glutamate pathways within the basal ganglia become overactive, leading to the suggestion that glutamate antagonists might possess antiparkinsonian qualities. This report examines the motor properties of antagonists of NMDA and AMPA-type glutamate receptors, as well as some inhibitors of glutamate release, in animal models of idiopathic Parkinson's disease. High affinity NMDA open-channel blockers (e.g. MK 801, phencyclidine), are highly potent antagonists with inconsistent antiakinetic and strong myorelaxant activity. Other compounds are better tolerated and are capable of relieving immobility and muscular rigidity by themselves (e.g. 1-aminoadamantanes, polyamine site antagonists, κ agonists, riluzole). Yet others do not restore movements alone (e.g. dextromethorphan, ketamine), but may interact with and strengthen the antiparkinsonian action of l-DOPA (e.g. competitive NMDA and AMPA antagonists, lamotrigine). They may do this by potentiating dopaminergic behaviours mediated by D1 or D2 receptors, or by some other mechanism.
Elsevier
以上显示的是最相近的搜索结果。 查看全部搜索结果